Artis Ventures
VC Fund
San Francisco, United States
ARTIS Ventures is a financial services firm that finances early-to-late-stage venture investments. The team supports its portfolio companies through their entire life cycle, from initial venture investment to public offering and beyond.
- Total investments:
- 145
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Artis Ventures invests in
Stages Artis Ventures invests in
Countries Artis Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2M–$47M
- Series A
- $5M–$57M
- Series B
- $20M–$127M
Investment Focus
Industry
- Health Care 25 (17%)
- Biotechnology 25 (17%)
- Software 16 (11%)
- Medical 13 (9%)
- Information Technology 10 (7%)
Stage
- Series A 33 (23%)
- Series B 26 (18%)
- Seed 21 (14%)
- Series C 19 (13%)
- Series D 10 (7%)
Country
- United States 81 (56%)
- United Kingdom 2 (1%)
- India 1 (1%)
- Germany 1 (1%)
- Ireland 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew McLean
Analyst
|
Analyst | Total investments: 0 | Find email | |
Austin Walne
Partner
|
Partner | Total investments: 7 | Find email | |
Henry Klingenstein
Partner
|
Partner | Total investments: 0 | Find email | |
Jeff Sheedy
Director of International Marketing
|
Director of International Marketing | Total investments: 0 | Find email | |
Megan Daugherty
Director of Communications and Administration
|
Director of Communications and Administration | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Arkenstone Defense
|
Arkenstone Defense provides an operating infrastructure platform that integrates government contracting and regulatory compliance into a centralized system for commercial technology companies. The platform manages complex defense requirements, including cleared workforce payroll, personnel security, audit readiness, and technical accreditationframeworks like CMMC and FedRAMP. By embedding these back-office operational controls directly into client environments, the company eliminates the administrative barriers that prevent commercial innovators from selling to the federal market. | $35M / Seed / Jul 07, 2026 | |
Onto Health
|
Onto Health offers a suite of fertility and reproductive health services delivered through technology-enabled clinics. It supports individuals and couples with personalized fertility assessments, IVF, IUI, egg freezing, tubal reversal, LGBTQ+ family-building solutions, embryo screening, and embryo banking. It also provides additional care such asgynecology, PCOS management, semen analysis, weight management for fertility, and remote cycle monitoring. It integrates digital tools, including online appointment booking, telehealth visits, patient portals, transparent pricing, and insurance guidance, to streamline care and support throughout the entire reproductive journey. The organization partners with TMRW Life Sciences to ensure automated cryogenic storage with monitoring, RFID tracking, and regulatory compliance. Its clinical model emphasizes tailored treatment pathways based on initial assessments, aiming to provide well-coordinated and supportive reproductive care experiences. | $20M / Series A / Apr 15, 2026 | |
Unnatural Products
|
Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.Unnatural Products was founded in 2017 and is headquartered in Santa Cruz,California. | $45M / Series B / Mar 16, 2026 | |
Luminate
|
Luminate is an oncology-focused healthtech and tech-enabled services company that partners with payers, providers, and people with cancer to reduce the cost of cancer care while improving quality of life and outcomes for patients. The company offers a portfolio of services and technologies that enable home-based cancer treatment, adverse eventmonitoring, and prevention of drug-induced side effects. | $21M / Series A / Jan 07, 2026 | |
Cartography Biosciences
|
Cartography is shaping a world in which cancer immunotherapies are designed around and directed toward the safest and most effective targets. | $67M / Series B / Oct 02, 2025 | |
Affect
|
Affect Therapeutics is using mobile technology to revolutionize stimulant addiction recovery. | $26M / Series B / Sep 23, 2025 | |
Conceivable Life Sciences
|
Conceivable Life Sciences is building the first fully automated IVF lab to democratize access to IVF. | $50M / Series A / Sep 15, 2025 | |
Valarian Technologies
|
We’re on a mission to help enterprises ensure their communication tools are secure, compliant and efficient.Valarian’s software allows multinational organisations to make the communication tools they already use compliant with data sovereignty, protection and privacy laws across jurisdictions worldwide. Valarian’s resilient, scalable platform canbe deployed into any environment (on-prem, cloud, or hybrid) and easily integrates with existing business collaboration tools like Microsoft Teams and WhatsApp, harmonising compliance, security and efficiency. | $7M / Seed / May 08, 2025 | |
Network Bio
|
Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools. | $17M / Seed / Feb 27, 2025 | |
Delfina
|
Delfina provides a personalized prenatal care system that uses the power of data to keep moms and babies safe during pregnancy. Their data-driven approach is uncovering unique insights in prenatal care to pave the way for clinical innovation. | $17M / Series A / Jan 28, 2025 | |
| See all 145 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Artis Ventures invest in?
Artis Ventures invests primarily in Health Care, Biotechnology and Software startups, most often at Series A and Series B stage. Most of the 145 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Artis Ventures's check size?
Artis Ventures typically joins rounds of $2M–$47M at Seed, $5M–$57M at Series A and $20M–$127M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Artis Ventures participates in.
How do I contact Artis Ventures?
Public channels for Artis Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Artis Ventures?
The team at Artis Ventures includes Andrew McLean (Analyst), Austin Walne (Partner) and Henry Klingenstein (Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
